Research and Markets: Biobetters - Major Players and Market Prospects

DUBLIN--(BUSINESS WIRE)-- Research and Markets (http://www.researchandmarkets.com/research/83e5da/biobetters_major) has announced the addition of the "Biobetters - Major Players and Market Prospects" report to their offering.

On paper, the numbers look good: Worldwide, biological drugs generate more than $120 billion in revenue.

From monoclonal antibody therapies and glycoproteins to vaccines and blood factors, biopharmaceuticals seem to have a healthy and expanding bottom line, particularly in emerging and increasingly wealthy Asian and South American markets.

But beyond the ledger, there is a different story. As more and more of the earliest, first generation biologicals such as human insulin and early recombinant forms of human growth hormone become patent-expired, they are thrown into competition with biosimilars generic versions of the same drug. The impact on the industry is undeniable: The rising cost of existing and expensive biopharmaceuticals contrasted with the lower price point and increasing availability of biosimilars are expected to hit the global market hard.

The solution may lie with biobetters. Already, innovation leaders like Novo Nordisk, Merck & Co and Roche are breaking ground and building on first generation biopharmaceuticals to create newer versions of expired-patent biologicals that do the job smarter, faster or with a better side-effect profile.

While most first generation biologicals are immediate-release and delivered subcutaneously or via infusion, for example, biobetters make a good thing even better. Modified by protein or glyco-engineering, they are more efficacious, require a lower dosing frequency and, most critically, reduce the risk of immunogenicity. Even better, they have lower early-stage R&D costs.

But the question remains: Will biobetters be competitive enough to strengthen pharmas bottom line?

Key insights and strategies from innovators and thought leaders in this compelling investigation into the current state of play between biosimilars and biobetters sets the tone and informational basis upon which the industry must act. Based on solid analysis, research and interviews with key thought leaders, the report examines how biosimilar drugs are being received in Europe and Japan, reviews the developing American regulatory environment and identifies the key strategists and leaders in biobetter advances. The report includes a breakdown of commercial areas and a detailed analysis of new technology, novel formulations and innovative manufacturing methods that, along with an emerging biological pipeline, will keep the industry competitive and on track.

The report investigates the biological drug market to determine:

  • Key strategies for establishing a cutting-edge, competitive biobetter market
  • Which industry innovators are producing new bio-technologies, manufacturing and engineering advances
  • The report Scans the current biological market environment to establish the impact of patent-expired biopharmaceuticals on future drug pricing, reimbursements, competition and R&D strategies
  • Offers a detailed analysis of biobetter strategies from innovation leaders
  • Identifies key marketing and development targets for biobetter advancement
  • Fully examines events in the most critical commercial biopharmaceutical areas, such as monoclonal antibodies, vaccines, glycoproteins, blood factors and insulin
  • Includes insights from industry thought leaders who identify key development opportunities
  • Offers critical observations regarding the need to substantively differentiate biobetters from biosimilars

Key Topics Covered:

Executive summary

Biosimilars and the High Demand for New Biological Drugs

Biobetters

Challenges in Biobetter Development

Opinions of Thought Leaders on the Future of Biobetters

Biobetter Strategies

Leading Biobetter Companies

Conclusion

Abbreviations

Index

Companies Mentioned:

  • Novo Nordisk
  • Merck & Co.
  • Roche Group
  • Biogen Idec
  • Amgen
  • Sanofi-Aventis
  • Eli Lilly
  • GlaxoSmithKline
  • Novartis
  • AstraZeneca
  • Pfizer

For more information visit http://www.researchandmarkets.com/research/83e5da/biobetters_major



CONTACT:

Research and Markets
Laura Wood, Senior Manager
[email protected]
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

KEYWORDS:

INDUSTRY KEYWORDS:   Health  Biotechnology

MEDIA:

Logo
 Logo

Suggested Articles

Across its 15-year history, Omega Funds has a hand in a clutch of high-profile biotechs such as Editas Medicine and Juno Therapeutics.

After Novartis’ near $10 billion buyout of The Medicines Company, many thought cardiovascular therapies were hot again.

The data position Leo to file for approval of the Dupixent rival in atopic dermatitis next year.